Everest Organics Limited said that it has developed and launched Posaconazole, an anti-fungal API for the treatment of black fungus associated with Covid-19 patients.

Posaconazole is a triazole antifungal agent indicated for treating mucormycosis (or Black Fungus) which has become prevalent in several Covid patients during the second wave in India.

Dr. Srikakarlapudi Sirisha – Director of Everest Organics said: “The Everest Organics Limited has successfully developed the API Posaconazole using its own in-house R&D strength at lab scale in short span of time. Further we are in advance stage of commercializing the same. Everest has successfully in near past launched and commercialized ‘Oseltamivir’ and ‘Remdesivir‘ both being used for Covid-19.

“Now we are more confident and are poised for development of more niche products in the quickest span of time because of our R&D strength.”

  Black Fungus, COVID-19, Dr. Srikakarlapudi Sirisha, Everest Organics, India, mucormycosis, Posaconazole